Profile image
Story Views

Last Hour:
Last 24 Hours:

Hyperuricemia Therapeutics Market Pipeline Review, H2 2016

Thursday, November 10, 2016 2:56
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Latest Hyperuricemia Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Hyperuricemia therapeutics industry report provides comprehensive information on the therapeutics under development for Hyperuricemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects.

Browse more detail information about Hyperuricemia market report at:

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Hyperuricemia – Pipeline Review, H2 2016:

  • Allena Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • CymaBay Therapeutics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Nippon Chemiphar Co., Ltd.
  • Nobelpharma Co., Ltd.
  • Polaris Pharmaceuticals, Inc.
  • Teijin Pharma Limited

Get a PDF Sample of Hyperuricemia Market Research Report at:


Drug Profiles of Included in Hyperuricemia Therapeutics Development Market Report

  • ALLN-346
  • Arhalofenate
  • febuxostat

And other drug profiles


Have any query? ask our expert @

Key Topics Covered:
2.Hyperuricemia Overview
3.Hyperuricemia Therapeutics Development
4.Pipeline Products for Hyperuricemia – Overview
5.Pipeline Products for Hyperuricemia – Comparative Analysis
6.Hyperuricemia – Therapeutics under Development by Companies
7.Hyperuricemia – Therapeutics under Investigation by Universities/Institutes
8.Hyperuricemia Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Hyperuricemia – Products under Development by Companies
13.Hyperuricemia – Products under Investigation by Universities/Institutes
14.Hyperuricemia – Companies Involved in Therapeutics Development
15.Hyperuricemia Drug Profiles
16.Hyperuricemia Dormant Projects
17.Hyperuricemia Discontinued Products
18.Hyperuricemia Featured News & Press Releases
And Continue…

Get Discount on Hyperuricemia Market Research Report at:

This 71 pages research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hyperuricemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email – [email protected]


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.